ADC Therapeutics Stock

adctherapeutics.comHealthcare / BioTech & PharmaFunding to Date: $200.02MM

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Register To Buy and Sell Shares

For more details on financing and valuation for ADC Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ADC Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ADC Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Susan Romanus
Chief Compliance Officer
Stéphane Henchoz
Director, Finance
David Ellis Ph.D
Head of Global Regulatory Affairs
Patrick Van Berkel Ph.D
Senior Vice President, Research & Development
Michael Forer
Vice Chairman, Executive Vice President & Chief Financial Officer
Maria Cincotta
Head of Global Clinical Science and Operations
Jay Feingold Ph.D
Chief Medical Officer, Senior Vice President Head of Oncology Clinical Development
Richard Warburg Ph.D
Head, Intellectual Property
Chris Martin Ph.D
Chief Executive Officer & Board Member
Michael Mulkerrin Ph.D
Head of Chemistry Manufacturing and Control & Vice President
Esohe Idusogie Ph.D
Head of Process Quality and CMC Analytical
Richard Onyett
Vice President, Business Development

Board Members

Chris Martin Ph.D
Jacques Theurillat
Peter Corr Ph.D
Auven Therapeutics
Thomas Pfisterer
Wild Family Office
Barrie Ward Ph.D
Stephen Evans-Freke
Auven Therapeutics
Tyrell Rivers Ph.D
Peter Hug Ph.D
Thomas Rinderknecht Ph.D
Updated on: Dec 10, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.